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Abstract.  The binding of lymphocytes to high en- 
dothelial venules (HEV) within peripheral lymph 
nodes (pin)  is thought to be mediated by a lectinlike 
adhesion molecule termed the pin homing receptor 
(pin  HR). The cloning and sequencing of cDNAs en- 
coding both murine and human pin HR revealed  that 
these adhesion molecules contain protein motifs that 
are homologous to C-type or calcium dependent lectin 
domains as well as to epidermal growth factor (egf) 
and complement-regulatory protein domains. We have 
produced a novel,  antibody-like form of the murine 
HR by joining the extracellular region of the receptor 
to a human IgG heavy chain. This antibody-like mole- 
cule is capable of recognizing carbohydrates, blocking 
the binding of lymphocytes to pin HEV,  and serving 
as a histochemical reagent for the staining of pin 
HEV.  This murine HR-IgG chimera should prove use- 
ful in analyzing the distribution of the HR ligand(s)  in 
normal as well as in inflammatory states. 
YMPHOCYTES bind to and extravasate through specialized 
high endothelial  venules  (HEV) ~ that  are  found in 
secondary lymphoid  organs such as peripheral lymph 
nodes (pln) and Peyer's patches (pp) (8, 15, 42, 52, 53). The 
ability of lymphocytes to migrate  selectively to one lym- 
phoid organ as compared to others has been termed homing. 
There is evidence that a set of diverse adhesion receptors on 
lymphocytes ("homing receptors";  HR) may be involved in 
the ability of lymphocytes to home to different anatomical 
regions such as pin, pp, and lung (8, 10, 16). While the bio- 
chemical identities of the lymphocyte homing receptors and 
their cognate endothelial cell ligands are only beginning to 
be understood,  it seems likely that these systems are inti- 
mately involved in not only the trafficking of lymphocytes to 
the organized lymphoid organs of the body but also in the 
extravasation of various leukocytes at sites of inflammation 
(22, 24, 25, 29, 33, 37). 
The  best-characterized  adhesion  molecule  involved in 
lymphocyte  homing  is  the  90-kD  glycoprotein  (gp90  MEL) 
defined on mouse lymphocytes by the MEL-14 mAb. Closely 
related  proteins  of somewhat greater molecular  mass are 
present on the surfaces of neutrophils and monocytes (29). 
Initial studies demonstrated that the MEL-14 mAb blocks the 
attachment of lymphocytes to pin HEV both in vitro and in 
vivo (15, 32) but has no effect on their binding to pp HEV. 
In addition, the presence of the MEL-14 defined epitope on 
various lymphocyte and  lymphoma populations  correlates 
1.  Abbreviations used in this paper:  egf,  epidermal growth factor;  HEV, 
high endothelial  venules;  HR,  homing receptor;  M6P, mannose-6-phos- 
phate;  pin,  peripheral  lymph nodes; pp, Peyer's patches. 
with the ability of the cells to bind to pin HEV (15, 34). Re- 
cently,  it  was  found that purified  gp90 uEL, when  reacted 
with sections of  lymphoid organs, blocks the binding oflym- 
phocytes to pin HEV but not to pp HEV, suggesting that the 
glycoprotein forms a direct bridge from the lymphocyte to 
endothelial ligands in an organ-restricted manner (17). Thus, 
the accumulated evidence warrants the designation periph- 
eral lymph node (pin) HR for gp90  MEL. Evidence developed 
in parallel to these studies has revealed that the murine pin 
HR (i.e.,  gp90 MEL) and its human homologue  function as 
calcium-dependent,  lectinlike receptors.  In rat, mouse, and 
human  systems,  lymphocyte  attachment  to  pin  HEV,  a 
calcium-dependent  cellular  interaction  (7, 51), is competi- 
tively inhibited  by specific carbohydrates  such as  o-man- 
nose-6-phosphate (M6P), the M6P-rich polysaccharide called 
PPME,  and the sulfated fucose-rich polysaccharide known 
as fucoidin (43, 44, 46, 54). Studies examining the interac- 
tion of PPME with the  lymphocyte surface  in the mouse 
pointed to the mHR (i.e., gp90  MEL) as the relevant lectinlike 
receptor (54, 55). In agreement with this prediction, cDNAs 
for  gp90  MEL encode  a  transmembrane  protein  containing 
three adjacent extracellular protein motifs: a calcium-depen- 
dent ("C-type") lectinlike domain (11) at the amino terminus, 
an epidermal growth factor (egf)-like domain and two iden- 
tical repeats related to those found in a number of comple- 
ment-regulatory proteins (28, 39). Confirmation of  the lectin 
character  of gp90  MEL has come from the direct demonstra- 
tion that the isolated native protein exhibits calcium-depen- 
dent, carbohydrate-binding activity in an ELISA assay (21). 
The importance of  the lectin domain in HEV binding was re- 
cently  supported  by the  demonstration  that  the  MEL-14- 
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motif  (5) and by the finding that the adhesion-blocking activ- 
ity of isolated gp90  uEL on pin HEV can be prevented by co- 
incubation of the molecule with M6P and related sugars (17). 
These findings strongly argue that that the lectin domain of 
murine pin HR recognizes and binds to a carbohydrate-based 
ligand that is specifically expressed on the pln HEV. In sup- 
port of this model, the susceptibility of adhesive ligands on 
pin HEV to sialidase treatment has provided preliminary evi- 
dence for the existence of essential carbohydrate moieties on 
pin HEV (35,  36). 
Consistent with data on cross-species recognition of pln 
HEV by human and murine lymphocytes (44,  46) human 
cells express a closely related homologue of the murine pin 
HR that probably functions in an analogous manner (4, 38, 
49). Furthermore, at least two other adhesion molecules, the 
endothelial leukocyte adhesion molecule (ELAM-1) (2) and 
the platelet membrane granule protein, GMP 140/PADGEM 
(3,  23,  31), show the same arrangement of protein motifs 
as gp90  MEL and its human homologue, suggesting that this 
family of lectin egf complement-cell adhesion molecules or 
LEC-CAMs (42), may be widespread in the vascular system. 
Reagents that are able to specifically recognize the HR 
ligand on pin HEV might prove useful in analyzing the role 
of this adhesion system at sites of leukocyte extravasation 
(e.g., inflammatory foci) outside of organized lymphoid tis- 
sues. In addition, such reagents might also act as effective an- 
tiinflammatory drugs,  if  they  are  able  to  block  leuko- 
cyte-endothelial interactions. One method for the derivation 
of such reagents is to produce mAbs specific for HR ligands 
found on the surface of the endothelium of HEV (47, 48). 
As a novel approach, we have developed a chimeric protein 
containing the murine HR and the hinge and constant re- 
gions of the human immunoglobulin heavy chains (9), thus 
converting the pin HR into a monoclonal antibody-like mole- 
cule specific for the cognate adhesive ligand(s) expressed on 
pin HEV. In the present study, we demonstrate that this chi- 
mera exhibits the lectin properties and the adhesion-blocking 
activity of the native receptor. Additionally, we establish the 
utility of this protein as a histochemical reagent for staining 
of pin HEV. The results suggests that the receptor-IgG chi- 
mera may prove exceptionally useful in both the isolation of 
the HEV ligand(s) as well as in the examination of the role 
of this adhesion system in various inflammatory states. 
Materials and Methods 
Construction, Analysis, and Purification of Truncated 
mHR-IgG Chimera 
Starting with a previously described mHR-PRK5 expression plasmid (27, 
28) and a eDNA encoding a human heavy chain IgG (9),  we inserted an 
1,I00-bp Hind III fragment encoding the CHI-CH3 regions of the human 
IgGl constant region 3 prime of the poly A addition site of the mHR cDNA. 
This plasmid was converted to single-stranded template by using an m13 
origin of replication and the K07 helper phage, after which regions between 
the hinge and the second complement binding repeat (NH2 terminus to the 
putative trans-membrane region) were looped out with 48-mer oligonucleo- 
tides by in vitro mutagenesis (56). The resultant mutants were screened with 
32P-labeled 21-mer oligonucleotides spanning the deletion junctions, and 
the isolated mutants were sequenced using supercoil sequencing. Correct 
mutants were tested for expression by transfection onto human kidney 293 
cells using previously described methods (27).  [35S]Methionine  and cys- 
teine  supernatants  were  analyzed by  immunoprecipitation with  protein 
A-Sepharose beads in the absence of added antibodies. The precipitated 
proteins  were  analyzed  on  7.5%  polyacrylamide-SDS gels  either  with 
(2-mercaptoethanol) or without reduction. Plasmids that resulted in cor- 
rectly expressed chimeras were introduced into 293 cells by transfection in 
the presence of selective plasmids encoding resistance to G418  as well as 
dihydrofolate reductase. Clones were selected in G418, and the incorporated 
plasmids were amplified in the presence of methotrexate (26). Permanent 
cell lines expressing high levels of mHR-IgG were grown to large scale in 
T-flasks or roller bottles, and the cell supernatants were clarified by centrifu- 
gation and filtration. The resultant supernatants were concentrated by filtra- 
tion (Amicon Corp., Danvers, MA) and passed over protein A-Sepharose 
columns, washed with PBS, and eluted with 0.1 M acetic acid, and 0.15 M 
NaCl (pH 3.5).  The eluted material was immediately neutralized with 3 M 
Tris (pH 9), and analyzed by SDS gel electrophoresis. Alternatively, con- 
centrated conditioned medium supernatants containing mHR-IgG chimeras 
were employed. Purified mHR-IgG chimera was quantified with an ELISA 
format in which an anti-human IgG1-Fc specific mouse mAb, coated onto 
microtiter wells, was used to capture the chimera protein. Unknown sam- 
ples and highly purified human CD4-1gGI  immunoadhesin (9) standard (the 
kind gift of S. Chamow, Department of Process Sciences, Genentech, Inc.), 
were incubated with antibody-coated plates, after which the plates were 
washed, and the bound material was reacted with HRP-conjugated goat 
anti-human IgGi, followed  by further washes and addition of substrate. This 
quantitative assay permitted the measurement of nanogram quantities of 
mHR-IgG chimeras. 
Analysis of mHR-IgG Chimera PPME Reactivity 
by ELISA 
The ability of the mHR-IgG chimera to recognize the yeast polyphospho- 
mannan (PPME),  was analyzed in an EL1SA  format as described (19). 
Briefly,  purified mHR-IgG chimera in Dulbecco's PBS was coated onto 
Immulon-2  microtiter plates  (Dynatech  Laboratories,  Inc.,  Alexandria, 
VA) overnight at 4°C.  Nonspecific sites were blocked with PBS-BSA at 
22°C, after which the bound antigens were reacted with PPME at 1 #g/rot. 
PPME was prepared from a core mannan preparation kindly provided by 
Dr. M. Slodki (U.S. Department of Agriculture, Northern Regional Center, 
Peoria, IL). Various additives, including MEL-14 mAb (10 #g/ml, final con- 
centration), carbohydrates, or EGTA (10 mM, final concentration), were 
added before PPME incubation in assays examining inhibition. After 1 h 
at 4°C, the plates were washed and incubated with a rabbit polyclonal anti- 
body directed against PPME for 1 h at 22°C. Plates were washed and in- 
cubated with biotinylated goat anti-rabbit IgG (Vector Laboratories, Inc., 
Burlingame, CA) for 1 h at 22°C followed by incubation with Vector ABC- 
alkaline phosphatase for 30 rain. The plates were developed after addition 
of substrate and read with a microplate reader. All determinations were car- 
ried out at least in triplicate. The background level, defined as the signal 
in the absence of PPME was subtracted from all values to yield the specific 
signal. Chondroitin sulfate A, beparin (porcine intestinal mucosa) and brain 
sulfatide were obtained from Sigma Chemical Co. (St. Louis, Me), and 
fucoidin came from K&K Laboratories (Plainview, NY). 
Cell Blocking  Assays with  mHR-IgG Chimera 
The  Stamper-Woodruff cell  blocking  assay  (51)  was  performed  with 
cryostat-cut sections of mouse pin and pp as previously described (17). The 
tissue sections were preexposed to buffer alone, purified mHR-IgG chimera, 
or gp90  MEL, which was purified and equilibrated in low detergent buffer as 
previously described (28). After the sections were washed, the lymphocyte 
adherence assay was carried out with mesenteric lymph node lymphocytes 
added at  1 x  107 cells/ml (17). Adherence was quantified by digital mor- 
phometry as the number of lymphocytes bound per unit area of HEV and 
referenced as a percentage of control binding in the absence of inhibitors. 
lmmunohistochemical Analysis of  mHR-IgG Chimera 
The mHR-IgG chimera was employed for histochemical staining based on 
standard procedures with mAbs. Briefly,  10-/zM tissue sections were cut in 
a cryostat and fixed with 0.5-1.0% paraformaldehyde in 0.1 M cacodylate 
(pH 7.3) for 20 rain at 4°C, followed by immersion in 100% methanol with 
0.3%  H202  for 20 min at 4°C to eliminate endogenous peroxidase. The 
sections were washed in Dulbecco's PBS and incubated for 60 rain at 4°C 
with the indicated amounts of mHR-IgG chimera (either protein A purified 
or as concentrated cell supernatants from culture medium) diluted in 5% 
The Journal  of Cell Biology,  Volume 110, 1990  2222 Figure L Construction and expression ofa mHR-IgG chimera con- 
taining the lectin-egf complement binding motifs. (A) The protein 
domains of the murine homing receptor (mHR) are shown: NH2- 
terminal signal sequence (SS), lectin, egf,. and duplicated comple- 
ment  binding domains  (CBD),  transmembrane  anchor  domain 
(TMD), and a  short cytoplasmic sequence.  The truncated mHR- 
IgG chimera that  contains the lectin, egf,  and two complement 
binding motifs is shown below. This truncated protein is joined to 
a human heavy chain gamma-1 region immediately NH2-terminal 
to the hinge domain (H) such that this chimera contains the two 
cysteine residues (C) of the hinge responsible for immunoglobulin 
dimerization as well as the CH2 and CH3 constant regions. (B) 293 
cells were transiently transfected with an expression plasmid con- 
taining  mHRLEC-IgG  chimera,  labeled  with  [3~S]cysteine  and 
methionine, and the whole cell lysates (extracted in 1% NP-40/0.1% 
SDS) and secreted materials were precipitated with protein A-Sepha- 
rose beads in the absence of added antibody after which the re- 
sultant precipitates were eluted from the beads with SDS  in the 
presence or absence of the reducing agent 2-mercaptoethanoi and 
electrophoresed on SDS-polyacrylamide gels and subjected to au- 
toradiography. Reduced proteins: lane A, secreted material; lane B, 
whole cell lysate. Nonreduced protein: lane C, secreted material. 
For brevity, the mHRLEC-IgG chimera is referred to as mHR-IgG 
chimera in the text of the paper. 
normal mouse serum in PBS. The sections were then washed and incubated 
with either biotinylated goat anti-human  Fc-specific antibody (Vector Lab- 
oratories,  Inc.) or affinity-purified biotinylated goat anti-human lgG (Zy- 
med  Laboratories,  San  Francisco,  CA)  in PBS  containing 5%  normal 
mouse serum for 30 min at 22°C. Sections were washed and incubated with 
AEC peroxidase substrate (Biomeda, Foster City, CA) for 5-10 min. Final- 
ly, the sections were counterstained with aqueous hematoxylin (Biomeda) 
and viewed with a Nikon Optophot. 
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Figure 2. Binding of mHR-IgG to PPME. Purified mHR-IgG was 
quantified using an ELISA assay as described  in Materials and 
Methods. The purified chimera was coated onto microtiter wells 
and reacted with PPME, after which the bound PPME was detected. 
with a polyclonal antibody in conjunction with alkaline phospha- 
tase-ABC reagents (21). Inhibition with MEL-14 mAb was per- 
formed by preincubating mHR-IgG containing wells with the mAb 
(10/~g/ml) before addition of  PPME, while the calcium dependence 
of the HR-carbohydrate interaction was demonstrated by inclusion 
of 10 mM EGTA during the binding reaction. Inhibition of PPME 
binding with various carbohydrates was examined as described in 
Materials and Methods. 50 t~liter aliquots of chimera (1  t~g/ml) 
were used to coat the microtiter wells for the carbohydrate inhibi- 
tion studies. (Top) Binding of PPME to increasing quantities of 
mHR-IgG and inhibition of mHR-IgG-PPME binding with MEL-14 
mAb and EGTA. In the absence of added PPME, the curve was 
identical to the +PPME+EGTA and the +PPME+MEL-14 mAb 
conditions. (Bottom) Inhibition of mHR-IgG-PPME binding with 
carbohydrates. 
Results 
Production of a Murine HR-Human lgG Chimera 
We chose to produce a receptor-immunoglobulin constant 
region chimera for several reasons. First, the production of 
a chimeric IgG-containing molecule would allow us to pro- 
duce, purify, and quantify the amount of the chimera using 
relatively simple, available assays.  Second, the ability of this 
molecule to dimerize might be expected to add to the avidity 
of the interaction between the receptor and its ligand on the 
endothelial surface. Finally, we felt that inclusion of the IgG 
constant region would permit the use of the chimeric protein 
in  histochemical  studies  employing readily accessible  re- 
agents. 
A mHR-IgG chimera was produced by using a previously 
characterized human heavy chain IgG1 constant region cas- 
sette (9).  The choice of junctional sites between the mHR 
and human IgG sequences was guided by work with human 
CD4-IgG chimeras that demonstrated that the joining of the 
molecules near the hinge region resulted in chimeric mole- 
cules that were both efficiently synthesized and dimerized in 
the absence of any light chain production (9). In addition, 
the use of the human IgG1 constant region would eliminate 
cross-reactivity with endogenous murine IgGs in the immu- 
nohistochemical staining of mouse lymphoid organs. Fig.  1 
A  illustrates the chimeric molecule containing the lectin, 
egf, and complement-binding domains (mHRLEC-IgG) and 
the human IgG1 heavy chain region that was produced by in 
vitro deletion mutagenesis  (56).  The construct was  trans- 
fected into human kidney cells (27), and the synthesized pro- 
tein  (referred to as  mHR-IgG chimera) was  recovered by 
affinity chromatography with protein A-Sepharose beads. As 
shown in Fig.  1 B, the chimera was  efficiently synthesized 
and secreted in the transient transfection assays. The reactiv- 
ity of the chimera with protein A-Sepharose demonstrated 
that the constant region domain was normally folded. Fig. 
1 B also shows that this molecule dimerized under nonreduc- 
ing conditions,  indicating that the  hinge region was  fully 
functional in this chimera. Finally, the protein A reactivity 
also allowed for the purification of this chimera to near ho- 
mogeneity on protein A-Sepharose columns. Thus, this mol- 
ecule represents an antibody-like entity whose "variable" do- 
main may be said to be derived from the mHR while the 
constant  domain  is  derived  from  the  human  IgG~ heavy 
chain. 
Analysis of mHR-IgG Chimera for PPME Binding 
Previous studies demonstrated that gp90  MEL, either as a cell 
surface-associated molecule (44, 46,  54) or as an isolated 
molecule (17),  is able to bind to the M6P-rich polysaccha- 
ride, PPME. In both cases, MEL-14 mAb inhibits the inter- 
action as does EGTA, a chelator of calcium ions. We thus 
analyzed the ability of the mHR-IgG chimera to interact with 
PPME in an ELISA binding assay (21).  As described in ex- 
perimental procedures, this assay employs a microtiter for- 
mat in which the chimera was bound to plastic and allowed 
to react with PPME after which the amount of bound PPME 
was  detected  with  a  polyclonal  antibody  against  PPME. 
Since the mHR-IgG chimera contained the Staphylococcal 
protein A-binding human IgG1 constant region, the relative 
amounts of chimera contained in each well could be easily 
measured by the degree of binding to a protein A-peroxidase 
conjugate. 
As shown in Fig. 2, the binding of PPME to the mHR-IgG 
chimera was a direct function of increasing IgG chimera lev- 
els. The binding was quantitatively similar to that found with 
comparable quantities of gp90  MEL isolated from spleen lym- 
phocytes (21). The signal was inhibited by the MEL-14 mAb 
and was calcium dependent as inferred from the complete 
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Figure 3. Inhibition of  lymphocyte  attachment to pin HEV by mHR- 
IgG chimera and by gp90  uEL. Cryostat sections of pin and pp were 
pretreated with buffer alone, purified mHR-IgG chimera or spleen- 
derived  gp90  MEL, both at  1 #g/section.  After the sections were 
washed, iymphocytes, that had been preincubated with 100 #g/ml 
aggregated human lgG to reduce Fc receptor  interactions, were 
added to the sections. Binding to HEV is expressed as a percentage 
of the value in the buffer control condition.  Error bars indicate 
SEMs based on four or more replicate sections for each treatment. 
Samples were coded and evaluated blindly and at least 15 segments 
of HEV were counted per section. (A) Inhibition of binding of lym- 
phocytes to pin HEV. (B) Lack of inhibition of binding of lympho- 
cytes to pp HEV. 
elimination of specific binding in the presence of EGTA (Fig. 
2  A).  Thus,  as  with  splenocyte-derived gp90  uEL, we con- 
clude that the C-type lectin domain of the chimera was re- 
sponsible for the interaction with PPME. 
Previous work has demonstrated that a variety of carbohy- 
drates in addition to PPME were recognized by the spleen 
derived mHR  (21,  54).  These active glycoconjugates in- 
cluded fucoidin and brain-derived sulfatide. The ability of 
these carbohydrates to inhibit the  interaction between the 
mHR-IgG chimera and PPME was examined to compare the 
specificity of this  molecule to  that of the  spleen-derived 
receptor (21).  As shown in Fig. 2 B, fucoidin and sulfatide 
were both effective  in inhibiting PPME binding to mHR-IgG, 
indicating that carbohydrate specificity was retained in the 
recombinant chimera.  The lack of inhibition by two other 
charged  carbohydrates,  chondroitin  sulfate  and  heparin, 
demonstrated that the inhibition resulted from specific car- 
bohydrate recognition and was not attributable to nonspe- 
cific charge interference (21). 
Analysis of the mHR-IgG Chimera in 
Cell Binding Assays 
While the above findings established that the mHR-IgG chi- 
mera recognized specific carbohydrates, they did not address 
the ability of this chimera to recognize ligands on the en- 
dothelium of pin HEV. Since previous work (17) has shown 
that gp90  MEL isolated from splenocytes by detergent extrac- 
tion is able to inhibit the binding of lymphocytes to pin sec- 
tions in the in vitro adherence assay (41),  we examined the 
activity of the IgG chimera in this cell binding assay.  As 
shown in Fig. 3 A, the mHR-IgG chimera (•1  #g/section), 
when prereacted with pin tissue sections, inhibited lympho- 
cyte attachment to HEV by *75 %. Spleen-derived gp90  MEL 
("~1 #g/section) was also active in the same assay. The lack 
of complete inhibition of lymphocyte binding by either the 
mHR-IgG chimera or the spleen-derived material may have 
been due to either insufficient quantities of  blocking proteins 
or of  accessory adhesion molecules such as the CD11/18 inte- 
grin system (13). Consistent with the previous findings with 
gp90  MEL (17), the mHR-IgG chimera did not affect the bind- 
ing oflymphocytes to pp HEV (Fig. 3 B). These results indi- 
cated that the mHR-IgG chimera was able to effectively  com- 
pete with lymphocytes for binding to HR ligands on pin but 
not on pp HEV. 
The Use of the mHR-IgG Chimera as a 
Histochemical Reagent 
The blocking of cell binding by the mHR-IgG chimera in the 
in vitro adherence assay implied that this molecule was capa- 
ble of a direct interaction with a ligand(s) on the pin HEV. 
Since this chimera contained the human IgG constant re- 
gion, we felt that it could be used as a histochemical reagent 
just as adhesion-blocking mAbs have been employed for the 
detection of potential ligands on HEV (47, 48). In the case 
of the mHR-IgG chimera, however, the actual HEV-ligand to 
which the mHR binds would be directly identified, and the 
issue of identity vs. proximity of the epitope-bearing mole- 
cule and the actual adhesive ligand would be avoided. The 
result would be a highly specific assay for the presence of the 
HR ligand not only on pin HEV but also at other endothelial 
sites where leukocytes use the mHR or related receptors for 
adherence and extravasation. 
Fig. 4 demonstrates that mHR-IgG chimera, used in con- 
junction with a  biotinylated goat anti-human IgG and the 
HRP-ABC reagent, stained pin HEV. The staining was al- 
ways  confined to the  high  walled  endothelial cells of the 
HEV. Other structures in the lymph node, including lympho- 
cytes and non-HEV blood vessels were negative. In many 
instances, the staining appeared to be concentrated on the 
Watson et al. Soluble HR-IgG Endothelial Interactions  2225 Figure 4.  Histochemical staining  of HEV with the mHR-IgG chimera. Cryostat-cut sections  of a mouse pin and a pp were reacted  with 
the chimera (3 #g of chimera/section, concentrated culture medium supernatant)  and processed for HRP histochemistry as described in 
Materials  and Methods.  (a) Staining  of pin, magnification  of 140. All the HEV are stained.  (b) A single pin HEV, magnification  at 560. 
Apical staining  of the endothelial  cells is apparent.  Since the tissue  section was paraformaidehyde-fixed  before exposure  to the chimera, 
the apical staining probably does not result from a homing receptor-induced redistribution  of ligand.  The occasional positive cells among 
the lymphocytes in the node parenchyma are due to nonspecific  staining.  Equivalent  staining  is seen in second-stage controls (no chimera 
added).  The staining associated with HEV is absent when chimera is not added.  Nonspecific  staining  is especially prevalent in medullary 
and subcapsular  sinuses  of nodes.  (c) A pin HEV magnification  at 560.  Staining  is seen across the entire  thickness of the HEV but is 
accentuated  at the luminal face of the HEV seen at the right.  Unstained  lymphocytes are present  in the lumen of the HEV and in the paren- 
chyma of the node.  (d) Two pp HEV, magnification  at 560.  The HEV, with their basement membranes delineated  by dashed lines,  are 
largely unstained.  Slight staining is present in the upper HEV. The tissue sections in c and d were stained  in parallel  under identical condi- 
tions. 
luminal surface of the specialized endothelial cells as com- 
pared to the basolateral surfaces (Fig. 4 B). The staining of 
HEV was blocked by co-incubation of the chimera with the 
MEL-14 mAb (Fig. 5 b) or with EGTA (Fig. 5 c), indicating 
that the binding of mHR-IgG to pin HEV mimicked the inter- 
action between lymphocytes and the HEV.  In concordance 
with the ELISA assay presented above, staining of pin HEV 
was inhibited by fucoidin (Fig.  5 d) but not by chondroitin 
sulfate (not shown). Thus, as previously shown indirectly for 
gp90  M~L  (17),  the  carbohydrate-binding  activity  of mHR- 
The Journal of Cell Biology, Volume 110,  1990  2226 Figure 5.  Inhibition of mHR-IgG chimera staining  of pin HEV. Sections  of pin were stained  with  1 #g/section of purified  chimera under 
four conditions.  (a) Control, no inhibitors  present.  Two stained HEV are evident, the top one in cross-section and the bottom one in longitu- 
dinal  section.  The staining  is not as intense  as that in Fig. 4. The parameters  responsible  for this variability  in control staining  are not 
understood. (b) In the presence of MEL-14 mAb, 5 #g/section. A single HEV (longitudinal section) with its basement membrane delineated 
by arrows is not stained.  (c) In the presence of  EGTA (10 mM, final concentration).  Three HEV indicated by arrows (cross-sectionalprofiles) 
are not stained.  (d) In the presence of fucoidin at 10 #g/section. An HEV in longitudinal  profile with its basement membrane delineated 
by arrows  is not stained.  Magnification  for all micrographs is 560. 
IgG was essential  for its interaction with pin HEV-ligands. 
Consistent with the failure of mHR-IgG or gp90  MEL to block 
the adhesive sites on pp HEV and the known involvement of 
a  distinct  adhesive system in this  interaction  (20),  the chi- 
mera  produced  very  faint  or  undetectable  staining  of the 
HEV in this lymphoid organ (Fig. 4  b).  This degree of dif- 
ferential staining was observed in over ten independent ex- 
periments.  However, in rare cases, moderate staining of pp 
HEV  was  seen,  although  the  intensity  was always signifi- 
cantly less than observed for pin HEV processed in parallel 
(not shown). 
Discussion 
The results reported in this paper describe the use of a solu- 
ble, recombinant form ofa HR as an antibody-like entity. By 
Watson et al. Soluble HR-IgG Endothelial Interactions  2227 cell adhesion experiments and histochemical staining, we 
have shown that this chimera can bind directly to pin HEV. 
Previous work converting a member of the immunoglobu- 
lin superfamily, CD4, to an IgG-like molecule or "immuno- 
adhesin" with potential as an anti-Human Immunodeficiency 
Virus drug revealed the utility of this procedure in generating 
new  types of "antibody-like" molecules  with tailor-made 
specificities (9).  The work described here establishes that 
nonimmunoglobulin superfamily receptors, such as the mHR, 
can also be converted to mAb-like molecules. The novelty 
of this approach is severalfold. First, it allows for the im- 
munohistochemical analysis of the distribution of a ligand 
for a cell adhesion receptor, even in the absence of an mAb 
specific for the ligand. In particular, the reagent described 
in this study, may be useful in mapping the vascular sites in 
the body where lymphocytes and perhaps other leukocytes 
bearing the receptor can traffic. Secondly, it is possible that 
this chimeric molecule may find utility as an antinflamma- 
tory reagent by virtue of its ability to block the binding of 
leukocytes to endothelium (see below). Third, the IgG chi- 
mera may be exploited as an affinity reagent to isolate en- 
dothelial ligands. Finally, the fact that a nonimmunoglobulin 
superfamily member  was  successfully produced and em- 
ployed here suggests  that this procedure may be of general 
applicability. 
Our histochemical analysis with the mHR-IgG chimera 
definitively establishes that this adhesion molecule can bind 
directly to the endothelial cells of pln HEV, thus extending 
the previous finding that spleen-derived mHR can block the 
binding  of iymphocytes to  pin  HEV  (17). The  observed 
staining was over the entire thickness of  the endothelial cells, 
but was frequently concentrated over the apical aspect of the 
cells where initial contact with lymphocytes is made. Con- 
ceivably,  the  uniform  staining  represents  a  cytoplasmic 
precursor form of the ligand, whereas the apical staining 
signifies a polarized cell surface expression of the ligand. A 
fine structural analysis, using the chimera for EM immuno- 
cytochemical localization, is required to provide a detailed 
description of the ligand's localization on the cell surface and 
within the cell. While the nature of the ligand is currently 
unknown,  previous  work has  identified a  pin  endothelial 
antigen that is recognized by the adhesion-blocking mAb 
MECA-79, and may, therefore, function as a HEV ligand for 
lymphocytes (48). Whether this antigen is the cognate ligand 
of the mHR-IgG chimera or is sterically close to the ligand 
is a subject for future investigation. 
The predominant lack of staining of pp HEV by the mHR- 
IgG chimera and the failure of the chimera to block lympho- 
cyte binding to this endothelium in vitro was anticipated 
from previous results  (15, 17,  20).  The findings reported 
herein  provide  the  first  direct  confirmation that  the  en- 
dothelial ligand for the pin mHR is distributed in an organ- 
restricted manner. Presumably, the ligand for the pp HR will 
have the converse distribution.  Interestingly, in  some in- 
stances, we observed moderate staining of pp HEV with the 
chimera.  This observation may represent the existence of 
dual HEV-ligands within a single lymphoid organ, a situa- 
tion that is known to occur in mesenteric lymph nodes (8, 
35, 47). Presumably, a distinctive milieu of locally produced 
soluble factors (e.g., cytokines) is responsible for induction 
and maintenance of each of  the organ-restricted HEV-ligands 
(12,  19). Perhaps, during certain immune responses or in- 
flammatory processes, these signals are altered, and the re- 
gional specificities become obscured. Additional work will 
be required to address the physiologic or pathophysiologic 
significance of the expression of pin HR ligands on pp HEV 
when it occurs. 
As noted above, the ability to use the mHR-IgG chimera 
as an immunohistochemical reagent now permits us to inves- 
tigate the relationship between the expression of ligands on 
endothelial ceils in various regions and the ability of leuko- 
cytes to extravasate in these regions. Of particular interest 
is the possible induction of chimera reactive ligands on en- 
dothelial cells at sites of acute or chronic  inflammation. 
Motivating this interest is the evidence implicating the in- 
volvement of MEL-14 defined glycoproteins on both neutro- 
phils and monocytes in endothelial adhesion during inflam- 
matory processes (24, 25, 29).  If the ligand were detected 
on endothelial cells at a particular site of inflammation, the 
chimera should then be evaluated for its ability to inhibit the 
inflammatory response in vivo. The demonstrated activity of 
the chimera in blocking the in vitro adherence of lympho- 
cytes to HEV supports the possibility that leukocyte-endothe- 
lial interactions preceding inflammatory responses might be 
blocked in vivo.  However,  the likely involvement of a mul- 
tiplicity of parallel adhesion systems in leukocyte-endothe- 
lial interactions during inflammatory reactions (1, 3,  13, 18, 
24, 25, 30, 40, 50) may limit the efficacy of any particular 
blocking reagent as an antiinflammatory drug. Nonetheless, 
the chimeric protein described here, or drugs that mimic its 
ligands, merit consideration as potential therapeutic reagents 
against inflammatory diseases. 
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